ARC Capital in the Australia-China biotech invest

ARC Capital in the Australia-China biotech invest

Last Monday, ARC Capital was involved in the Australia-China biotech invest 2017, the place to find Biotech innovators from around the world and partnership opportunities. with leading-edge technologies.

The program took place on Monday 27 March at the Marriott in Shanghai. The program featured company presentations, keynote speakers, lively panel discussions and was the perfect location for us to meet potential clients.

We discuss with the following companies in order to cooperate together:

  • Petri Exchange
  • Biotron
  • Novogen
  • FivepHusion
  • ResApp

The upcoming partnerships is an indication of ARC Capital’s capabilities to assist both public and private listed companies.

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission